The U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application or sBLA for obinutuzumab (Gazyva®; Genentech/Roche) in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). The sBLA adds to the label data from Stage 2 of the CLL11 study showing significant improvements with Gazyva plus chlorambucil across multiple clinical endpoints when compared head-to-head with rituximab; Rituxan®;…Continue
Added by Editorial Team on December 24, 2014 at 1:00pm — No Comments
Data from a new analysis published early online in Cancer, a peer-reviewed journal of the American Cancer Society has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it.
Results published in 2004 from a large, randomized clinical trial showed that adding radiation therapy to surgery plus tamoxifen does not reduce 5-year recurrence rates or prolong…Continue
Added by Editorial Team on December 8, 2014 at 3:30am — No Comments